The combination of the cleavable linker, the membrane-permeable cytotoxic payload with high DAR, leads to increased activity on neighboring cells are all key features of the ADC structure, and allows for the use of T-DXd in cancers with heterogeneous HER2 expression, thus, lung cancer is a prime candidate for this compound. Here, ERBB2 is linked to cancer.